One of Bristol-Myers’s largest shareholders is opposing the company’s $74 billion deal to buy rival Celgene, becoming the latest investor to express its unhappiness with the transaction.
from WSJ.com: US Business https://ift.tt/2Vp3T2t
Subscribe to:
Post Comments (Atom)
The 5 most important work relationships you should prioritize for career growth — besides your boss
Maskot/Getty Images Career growth depends on building a network rather than relying solely on your manager's support. Career coac...
-
Caroline Purser/Getty Images The S&P 500 has shed 4% since the beginning of the year as Big Tech stocks decline. However, previou...
-
The Bell V-280 Valor was selected as the Army's future long-range assault aircraft in 2022. Photo courtesy of Bell The US Army desi...
-
Big Tech is emerging a winner in the new H-1B system, while early-stage startups could lose out. Matthias Balk/nirat/Getty/Getty Images ...
No comments:
Post a Comment